1. Apoptosis Anti-infection
  2. Apoptosis Parasite
  3. Asiatic acid

Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model.

For research use only. We do not sell to patients.

Asiatic acid Chemical Structure

Asiatic acid Chemical Structure

CAS No. : 464-92-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 27 In-stock
Solution
10 mM * 1 mL in DMSO USD 27 In-stock
Solid
5 mg USD 25 In-stock
10 mg USD 35 In-stock
50 mg USD 70 In-stock
100 mg USD 98 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Asiatic acid:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
518A2 EC50
21.9 μM
Compound: AA
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
8505C EC50
16.8 μM
Compound: AA
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A2780 EC50
28.2 μM
Compound: AA
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A-375 IC50
50.33 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
[PMID: 26974379]
A549 IC50
> 100 μM
Compound: AA
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
A549 IC50
> 20 μM
Compound: AA
Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer
Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer
[PMID: 31057738]
A549 IC50
18.8 μM
Compound: AA 6
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 28754470]
A549 EC50
26.2 μM
Compound: AA
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A549 IC50
37.81 μM
Compound: AA 6
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 28754470]
A549 IC50
41.02 μM
Compound: AA
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 31057738]
BJ IC50
88.7 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human BJ cells after 72 hrs by MTT assay
Cytotoxicity against human BJ cells after 72 hrs by MTT assay
[PMID: 26974379]
CHO EC50
> 10 μM
Compound: Asiatic acid
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
[PMID: 19911773]
COS-1 EC50
0 μM
Compound: Asiatic acid
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
[PMID: 19911773]
Epithelial cell IC50
> 20 μM
Compound: asiatic acid
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
[PMID: 18826277]
H9 IC50
9 μg/mL
Compound: 8
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
[PMID: 9748372]
HeLa IC50
37.26 μM
Compound: AA
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 25151580]
HeLa IC50
4 μM
Compound: AA 6
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 28754470]
HeLa IC50
52.47 μM
Compound: AA 6
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 28754470]
HeLa IC50
52.47 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 26974379]
HeLa IC50
91.07 μM
Compound: AA
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
HepG2 IC50
> 10 μM
Compound: 24
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 27797185]
HepG2 IC50
34.9 μM
Compound: AA
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 25151580]
HepG2 IC50
35.37 μM
Compound: AA
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 31057738]
HT-29 EC50
> 30 μM
Compound: AA
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
HT-29 IC50
64.3 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 26974379]
HT-29 IC50
64.33 μM
Compound: AA 6
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 28754470]
HUVEC IC50
> 100 μM
Compound: AA 6
Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 28754470]
HUVEC IC50
> 100 μM
Compound: AA
Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay
Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay
[PMID: 25151580]
Jurkat IC50
37.17 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
[PMID: 26974379]
L02 IC50
> 50 μM
Compound: AA
Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
[PMID: 31057738]
MCF7 IC50
> 10 μM
Compound: 24
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 27797185]
MCF7 EC50
> 30 μM
Compound: AA
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
MCF7 GI50
19.1 μM
Compound: AA 6
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
MCF7 IC50
32.8 μM
Compound: AA 6
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 28754470]
MCF7 IC50
67.58 μM
Compound: AA
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
MCF7 IC50
68.5 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 26974379]
MDA-MB-231 GI50
18.1 μM
Compound: AA 6
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
MGC-803 IC50
22.57 μM
Compound: AA
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
[PMID: 25151580]
MIA PaCa-2 IC50
50.67 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
[PMID: 26974379]
NCI-H460 IC50
39.55 μM
Compound: AA
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
[PMID: 25151580]
NCI-H460 IC50
44.82 μM
Compound: AA
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
[PMID: 31057738]
NCI-N87 IC50
> 10 μM
Compound: 24
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
[PMID: 27797185]
NIH3T3 EC50
26.2 μM
Compound: AA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
PC-3 IC50
53.6 μM
Compound: AA 6
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 28754470]
PC-3 IC50
67.25 μM
Compound: AA; Asiatic Acid
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
[PMID: 26974379]
RAW264.7 IC50
74.8 μM
Compound: 4
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
[PMID: 21353543]
RAW264.7 IC50
8.6 μM
Compound: 4
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 21353543]
Sf21 IC50
> 40 μM
Compound: 25
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
[PMID: 31774676]
SGC-7901 IC50
36.8 μM
Compound: AA 6
Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 28754470]
T-24 IC50
33.72 μM
Compound: AA 6
Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 28754470]
T-24 IC50
43.97 μM
Compound: AA
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
[PMID: 31057738]
In Vitro

Asiatic acid exerts barrier stabilizing effects against TNF-α by maintaining adherens junctions (AJs) and inhibiting tight junction (TJ) redistribution[2].
Asiatic acid (40 μM) stabilizes F-actin and diphosphate-MLC at the cell periphery and prevents their rearrangement stimulated by TNF-α (10 ng/mL; 1 h). However, Asiatic acid (10-30 μM; 6 h) cannot reduce F-actin aggregation[2].
Asiatic acid (40 μM; 6 h) preserves the network structure of cell-cell contact areas and abolishes TNF-α-induced structural reorganization of vascular endothelial (VE)-cadherin and β-catenin[2].
However, Asiatic acid (10-40 μM; 6 h) had no inhibitory effect on endothelial cell permeability increased by cytochalasin D (5 μM; 15 min). Asiatic acid increases the diphosphorylation of myosin light chain (MLC)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Asiatic acid (5-75 mg/kg; intragastric gavage once daily) effectively inhibited pelvic inflammatory disease (PID) in rats in a pathogen-induced disease model and exerted antioxidant and anti-inflammatory effect[3].
Asiatic acid (30 mg/kg, 75 mg/kg; intragastric injection, once daily) has neuroprotective effects on spinal cord injury (SCI) in rats by inhibiting inflammation and oxidative stres[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

488.70

Formula

C30H48O5

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1(CO)[C@@H](O)[C@H](O)C[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (511.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0462 mL 10.2312 mL 20.4625 mL
5 mM 0.4092 mL 2.0462 mL 4.0925 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.25 mg/mL (4.60 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (4.26 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.40%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0462 mL 10.2312 mL 20.4625 mL 51.1561 mL
5 mM 0.4092 mL 2.0462 mL 4.0925 mL 10.2312 mL
10 mM 0.2046 mL 1.0231 mL 2.0462 mL 5.1156 mL
15 mM 0.1364 mL 0.6821 mL 1.3642 mL 3.4104 mL
20 mM 0.1023 mL 0.5116 mL 1.0231 mL 2.5578 mL
25 mM 0.0818 mL 0.4092 mL 0.8185 mL 2.0462 mL
30 mM 0.0682 mL 0.3410 mL 0.6821 mL 1.7052 mL
40 mM 0.0512 mL 0.2558 mL 0.5116 mL 1.2789 mL
50 mM 0.0409 mL 0.2046 mL 0.4092 mL 1.0231 mL
60 mM 0.0341 mL 0.1705 mL 0.3410 mL 0.8526 mL
80 mM 0.0256 mL 0.1279 mL 0.2558 mL 0.6395 mL
100 mM 0.0205 mL 0.1023 mL 0.2046 mL 0.5116 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Asiatic acid
Cat. No.:
HY-N0194
Quantity:
MCE Japan Authorized Agent: